Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Devax Axxess bifurcated DES

This article was originally published in The Gray Sheet

Executive Summary

International trial of the Biolimus A9 drug- and polymer- coated nitinol coronary stent commences at two centers in Germany. Privately held, Irvine, Calif.-based Devax notes that the system is the first bifurcated stent to elute an anti-restenotic drug, estimating that 15%-20% of lesions are bifurcated. The start-up licensed the drug and polymer from Occam International - an affiliate of Biosensors International. The trial will assess acute and six-month results in treating bifurcated lesions in native coronary arteries. Enrollment likely will close by year-end...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT020613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel